PubRank

Paul Moayyedi

Author PubWeight™ 160.56‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 2013 4.29
2 Detection of intestinal metaplasia in Barrett's esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am J Gastroenterol 2007 4.14
3 Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008 4.12
4 Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011 3.97
5 Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010 3.32
6 Effect of comorbidity on mortality in patients with peptic ulcer bleeding: systematic review and meta-analysis. Am J Gastroenterol 2013 2.97
7 Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? JAMA 2008 2.89
8 Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012 2.68
9 Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005 2.56
10 Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013 2.53
11 Management of Barrett's esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am J Gastroenterol 2008 2.52
12 Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev 2010 2.47
13 Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006 2.46
14 American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005 2.39
15 Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005 2.36
16 Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut 2010 2.21
17 Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gastroenterology 2013 2.13
18 Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 2005 2.07
19 Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011 2.04
20 Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008 2.02
21 Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis. Crit Care Med 2013 2.01
22 Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007 2.00
23 Helicobacter pylori test and treat versus proton pump inhibitor in initial management of dyspepsia in primary care: multicentre randomised controlled trial (MRC-CUBE trial). BMJ 2008 1.98
24 EUS: a meta-analysis of test performance in suspected choledocholithiasis. Gastrointest Endosc 2008 1.85
25 Ulcerative colitis. BMJ 2013 1.76
26 Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009 1.67
27 Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis. Am J Gastroenterol 2011 1.60
28 Symptom-based outcome measures for dyspepsia and GERD trials: a systematic review. Am J Gastroenterol 2005 1.59
29 Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study. Gastroenterology 2010 1.58
30 Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev 2015 1.58
31 Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007 1.57
32 Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004 1.54
33 Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis. Arch Intern Med 2009 1.53
34 Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012 1.52
35 5-aminosalicylates prevent relapse of Crohn's disease after surgically induced remission: systematic review and meta-analysis. Am J Gastroenterol 2010 1.50
36 Inconsistent definitions for intention-to-treat in relation to missing outcome data: systematic review of the methods literature. PLoS One 2012 1.48
37 Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004 1.47
38 Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol 2008 1.44
39 An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011 1.42
40 Helicobacter pylori infection in functional dyspepsia. Nat Rev Gastroenterol Hepatol 2013 1.41
41 Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005 1.40
42 Acid-suppressive therapy with esomeprazole for relief of unexplained chest pain in primary care: a randomized, double-blind, placebo-controlled trial. Am J Gastroenterol 2012 1.40
43 Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol 2009 1.39
44 Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west. Gastroenterology 2002 1.36
45 Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2009 1.29
46 Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett's esophagus. Am J Epidemiol 2005 1.28
47 Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011 1.24
48 Canadian Helicobacter Study Group Consensus Conference: Update on the approach to Helicobacter pylori infection in children and adolescents--an evidence-based evaluation. Can J Gastroenterol 2005 1.17
49 Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2009 1.16
50 Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011 1.14
51 How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003 1.12
52 Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study. Am J Gastroenterol 2007 1.11
53 Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics. Contemp Clin Trials 2012 1.10
54 Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011 1.10
55 What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010 1.10
56 Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2006 1.08
57 Recommendations on chronic constipation (including constipation associated with irritable bowel syndrome) treatment. Can J Gastroenterol 2007 1.07
58 Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes. Gut 2013 1.05
59 Gastric Cancer Consensus conference recommends Helicobacter pylori screening and treatment in asymptomatic persons from high-risk populations to prevent gastric cancer. Am J Gastroenterol 2008 1.04
60 A community screening program for Helicobacter pylori saves money: 10-year follow-up of a randomized controlled trial. Gastroenterology 2005 1.02
61 Effect of dyspepsia on survival: a longitudinal 10-year follow-up study. Am J Gastroenterol 2012 1.02
62 Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2013 1.01
63 Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008 0.97
64 Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011 0.96
65 Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn? Am J Gastroenterol 2009 0.95
66 Randomized controlled trial comparing telephone and mail follow-up for recruitment of participants into a clinical trial of colorectal cancer screening. Trials 2013 0.93
67 Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis. Am J Gastroenterol 2011 0.93
68 Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators? Inflamm Bowel Dis 2010 0.93
69 Does long term aspirin prevent cancer? BMJ 2010 0.91
70 Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. Scand J Gastroenterol 2015 0.89
71 Stress ulcer prophylaxis in critically ill patients: review of the evidence. Pol Arch Med Wewn 2012 0.89
72 A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004 0.89
73 Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference. Am J Gastroenterol 2009 0.89
74 Effect of sibling number in the household and birth order on prevalence of Helicobacter pylori: a cross-sectional study. Int J Epidemiol 2007 0.87
75 Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2002 0.86
76 Guidewire-assisted cannulation of the common bile duct for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev 2012 0.85
77 Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol 2015 0.84
78 WITHDRAWN: Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2009 0.84
79 Effectiveness of disseminating consensus management recommendations for ulcer bleeding: a cluster randomized trial. CMAJ 2013 0.84
80 Managing dyspepsia. Curr Gastroenterol Rep 2009 0.83
81 Hip fracture and proton pump inhibitor therapy: position statement. Can J Gastroenterol 2008 0.83
82 Errors in the conduct of systematic reviews of pharmacological interventions for irritable bowel syndrome. Am J Gastroenterol 2009 0.83
83 Colorectal cancer screening with fecal occult blood testing (FOBT): an international perspective. Am J Gastroenterol 2006 0.83
84 Eradicating H pylori. BMJ 2004 0.83
85 Proton pump inhibitors and risk of bone fractures. Curr Treat Options Gastroenterol 2014 0.82
86 Current guidelines for dyspepsia management. Dig Dis 2008 0.82
87 Redundant data in the meta-analysis on Helicobacter pylori eradication. Ann Intern Med 2009 0.82
88 Barrett's esophagus and obesity: the missing part of the puzzle. Am J Gastroenterol 2008 0.80
89 Non-erosive reflux disease--defining the entity and delineating the management. Digestion 2008 0.80
90 WITHDRAWN: Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2010 0.80
91 A validation study of the Italian Short-Form Leeds Dyspepsia Questionnaire. Intern Emerg Med 2010 0.79
92 Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed 2006 0.78
93 Does aspirin really reduce the risk of colon cancer? Lancet 2012 0.78
94 A glossary of economic terms. Eur J Gastroenterol Hepatol 2004 0.78
95 Is it safe to use a proton pump inhibitor with clopidogrel? Pol Arch Med Wewn 2009 0.78
96 A second-order simulation model of the cost-effectiveness of managing dyspepsia in the United States. Med Decis Making 2007 0.78
97 The promises and perils of nurse-led flexible sigmoidoscopy screening. Can J Gastroenterol 2007 0.78
98 Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol 2009 0.78
99 Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2009 0.78
100 WITHDRAWN: Psychological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2011 0.77
101 Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis. Clin Gastroenterol Hepatol 2011 0.77
102 Dyspepsia. BMJ 2013 0.77
103 Endoscopic screening and surveillance for Barrett's esophagus--clinical implications. MedGenMed 2006 0.77
104 Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev 2016 0.77
105 Dyspepsia. Curr Opin Gastroenterol 2013 0.76
106 Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? Pol Arch Med Wewn 2009 0.76
107 Helicobacter pylori eradication therapy for nonulcer dyspepsia. Ann Intern Med 2002 0.76
108 Aspirin in the prevention of cancer. Lancet 2011 0.76
109 NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias. Lancet Oncol 2006 0.76
110 "Power" of selective serotonin reuptake inhibitors in irritable bowel syndrome. Clin Gastroenterol Hepatol 2009 0.76
111 Response to Nahon et al. and Marmo et al. Am J Gastroenterol 2013 0.75
112 The authors reply. Crit Care Med 2013 0.75
113 Tax-deductible provisions for gluten-free diet in Canada compared with systems for gluten-free diet coverage available in various countries. Can J Gastroenterol Hepatol 2015 0.75
114 Iron overload in human disease. N Engl J Med 2012 0.75
115 Dyspepsia results may not apply in primary care. BMJ 2003 0.75
116 Treatment of chronic gastro-oesophageal reflux disease. BMJ 2009 0.75
117 ACP Journal Club. Crohn disease was not associated with increased risk for mortality. Ann Intern Med 2013 0.75
118 ACP Journal Club. Review: Calprotectin testing differentiates inflammatory bowel disease from the irritable bowel syndrome. Ann Intern Med 2014 0.75
119 Measuring gastroesophageal reflux symptoms: musings from Marrakech. Am J Gastroenterol 2005 0.75
120 Bran and irritable bowels. Bran's deleterious effects: much ado about nothing. BMJ 2009 0.75
121 Reply to Kawakami et al. Endoscopy 2014 0.75
122 Gambling with gastroesophageal reflux disease: should we worry about the QALY? Am J Gastroenterol 2005 0.75
123 Canadian Association of Gastroenterology position statement: hip fracture and proton pump inhibitor therapy-a 2013 update. Can J Gastroenterol 2013 0.75
124 The American College of Gastroenterology irritable bowel syndrome monograph: translating systematic review data to clinical practice. Gastroenterology 2009 0.75
125 Helicobacter pylori infection. BMJ Clin Evid 2009 0.75
126 Helicobacter pylori infection. Clin Evid 2005 0.75
127 Management of reflux-related symptoms. Best Pract Res Clin Gastroenterol 2013 0.75
128 Pancreatic duct guidewire placement for biliary cannulation for the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. Cochrane Database Syst Rev 2016 0.75
129 Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis 2017 0.75
130 Helicobacter pylori infection. Am Fam Physician 2003 0.75
131 Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment. Value Health 2013 0.75
132 Helicobacter pylori infection. Clin Evid 2002 0.75
133 Helicobacter pylori infection. Clin Evid 2002 0.75
134 Helicobacter pylori infection. Clin Evid 2003 0.75
135 Helicobacter pylori infection. BMJ Clin Evid 2007 0.75
136 Helicobacter pylori infection. Clin Evid 2004 0.75
137 Cost-effectiveness and long-term impact of Helicobacter pylori 'test and treat' service in reducing open access endoscopy referrals. Eur J Gastroenterol Hepatol 2004 0.75
138 Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis 2017 0.75
139 Microbiome: fecal transplant in Clostridium difficile and ulcerative colitis. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 2. Pol Arch Intern Med 2017 0.75
140 Microbiome: the beginning of understanding. Dr. Paul Moayyedi in an interview with Dr. Roman Jaeschke: part 1. Pol Arch Intern Med 2017 0.75
141 Gastro-oesophageal reflux disease. Clin Evid 2004 0.75